Related Experiment Video
Updated: Jun 16, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
TRAIL-activated stress kinases suppress apoptosis through transcriptional upregulation of MCL-1
J K Son1, S Varadarajan, S B Bratton
1Center for Molecular and Cellular Toxicology, Division of Pharmacology and Toxicology, College of Pharmacy, University of Texas at Austin, Austin, TX 78712, USA.
Abstract:
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potentially useful anticancer agent with exquisite selectivity for cancer cells. Unfortunately, many cancers show or acquire resistance to TRAIL. In this study we report that TRAIL activates a TGF-beta-activated kinase 1 --> mitogen-activated protein kinase (MAPK) kinase 3 (MKK3)/MKK6 --> p38 pathway in prostate cancer cells that transcriptionally upregulates expression of the antiapoptotic BCL-2 family member MCL-1. TRAIL alone triggered robust formation of the 'death-inducing signaling complex' (DISC), activation of the initiator caspase-8, and truncation of the BH3-only protein BID (tBID). Nevertheless, simultaneous disruption of the p38 MAPK pathway was required to suppress MCL-1 expression, thereby allowing tBID to activate the proapoptotic BCL-2 family member BAK and stimulate mitochondrial outer membrane permeabilization (MOMP). Release of the inhibitor-of-apoptosis (IAP) antagonist, Smac/DIABLO, from the intermembrane space was sufficient to promote TRAIL-induced apoptosis, whereas release of cytochrome c and activation of the apoptosome was dispensable. Even after MOMP, however, mitochondrial-generated reactive oxygen species (ROS) activated a secondary signaling pathway, involving c-Jun N-terminal kinases (JNKs), that similarly upregulated MCL-1 expression and partially rescued some cells from death. Thus, stress kinases activated at distinct steps, before and after mitochondrial injury, mediate TRAIL resistance through maintenance of MCL-1 expression.
Insights
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) resistance in cancer is overcome by blocking the p38 MAPK pathway, which suppresses MCL-1 and allows apoptosis. This reveals a dual mechanism of TRAIL resistance involving stress kinases.
Area of Science:
- Cellular biology
- Molecular oncology
- Apoptosis signaling
Background:
- Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) shows promise as a cancer therapeutic due to its selective toxicity towards cancer cells.
- Acquired or intrinsic resistance to TRAIL limits its clinical efficacy in many cancer types.
Purpose of the Study:
- To elucidate the molecular mechanisms underlying TRAIL resistance in prostate cancer cells.
- To identify signaling pathways that mediate resistance and explore strategies to overcome it.
Main Methods:
- Investigated TRAIL-induced signaling pathways, including the p38 MAPK and JNK pathways.
- Analyzed the role of MCL-1, BCL-2 family proteins, and mitochondrial outer membrane permeabilization (MOMP) in TRAIL response.
- Utilized pharmacological inhibitors to disrupt specific signaling cascades.
Main Results:
- TRAIL activates a p38 MAPK pathway that upregulates antiapoptotic MCL-1, hindering apoptosis.
- Disrupting the p38 MAPK pathway suppressed MCL-1, enabling TRAIL-induced apoptosis via BAK activation and Smac/DIABLO release.
- Mitochondrial reactive oxygen species (ROS) activated JNK, leading to secondary MCL-1 upregulation and partial resistance even after MOMP.
Conclusions:
- Stress kinases, p38 MAPK and JNK, mediate TRAIL resistance by sustaining MCL-1 expression at distinct stages of the apoptotic process.
- Targeting these stress kinase pathways, particularly p38 MAPK, is a potential strategy to enhance TRAIL-based cancer therapies.
Related Concept Videos
MAPK Signaling Cascades
The Intrinsic Apoptotic Pathway
PI3K/mTOR/AKT Signaling Pathway
The JAK-STAT Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
